Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:55:57.558Z.
Consensus retrieved: 2026-10-06T09:12:28.788Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:55:57.558Z.
Quote observation: 2026-10-06T14:55:25.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 47c8a7f7872550f4b91559d6c77d4467729e005a9c3786f3e3eb9faa26d80d2a
Forward PE Ratio (N/A) = Dated Quote Price ($13.67) / Consensus Forward EPS ($-2.92)
FORWARD PE RATIO
N/A
Avalo Therapeutics, Inc.
Market Cap
$718.57M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | $718.57M | N/A |
| Cytek Biosciences, Inc. (CTKB)vs › | $716.10M | N/A |
| Achieve Life Sciences, Inc. (ACHV)vs › | $726.83M | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $708.19M | N/A |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $707.95M | N/A |
| Faeth Therapeutics, Inc. (FTH)vs › | $704.02M | N/A |
| Anteris Technologies Global Corp. (AVR)vs › | $692.29M | N/A |
| Candel Therapeutics, Inc. (CADL)vs › | $753.58M | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $755.11M | N/A |
| Annexon, Inc. (ANNX)vs › | $676.72M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $13.67, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-2.92 | $-3.71 – $-2.16 | 8 | n/m |
| 2027-12-31 | $-2.98 | $-4.25 – $-2.35 | 9 | n/m |
| 2028-12-31 | $-3.34 | $-4.37 – $-2.07 | 6 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
